Truist raised its price target for Eli Lilly to $1,612 from $1,376 and still recommends buying.

Oct 30, 2026, 7:03 AM ETOpinionRead the original at marketscreener.com

Good for LLY

Truist raised its price goal for Eli Lilly and kept its Buy rating, supporting a more hopeful view of the shares. The story gives no new company results to confirm better business performance.

LLY · Eli Lilly and Company

AI read · Good for LLY

The AI's read

A higher price goal and continued Buy rating show Truist sees more room for Eli Lilly shares to rise. The story gives no new sales, trial, or profit figures, so this is a favorable opinion, not proof of stronger results.

Get alerts for LLY

Follow Eli Lilly and Company (LLY) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for LLY

Free on the App Store and Google Play, or on the web.